{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(5)"],"submitter":["Signorelli D"],"pubmed_abstract":["<h4>Background</h4>Malignant pleural mesothelioma (MPM) is an aggressive tumor but approximately 12% of patients survive more than 3 years. The biological differences underlying better outcomes are not known. Several targeted agents and immunotherapy have been ineffective. Hedgehog (Hh) is one emerging pathway. We compared the biological profiles of patients with different survival, investigating the most frequently altered genes, including the Hh pathway.<h4>Methods</h4>We analyzed 56 MPM. A 36-month overall survival (OS) cut-off divided patients into 32 normo (NS) and 24 long (LS) survivors. We used next generation sequencing to test 21 genes, immunohistochemistry to evaluate SMO expression. Mutation differences between NS and LS and their associations with clinical features were analyse"],"journal":["Translational lung cancer research"],"pagination":["1940-1951"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7653142"],"repository":["biostudies-literature"],"pubmed_title":["<i>SMO</i> mutations confer poor prognosis in malignant pleural mesothelioma."],"pmcid":["PMC7653142"],"pubmed_authors":["de Braud F","Ganzinelli M","Pastorino U","Trama A","Garassino MC","Proto C","Tamborini E","Signorelli D","Tiseo M","Ferrara R","Pasello G","Busico A","Prelaj A","Galli G","Fabbri A","Gatta G","Lo Russo G","Imbimbo M","Botta L","De Toma A"],"additional_accession":[]},"is_claimable":false,"name":"<i>SMO</i> mutations confer poor prognosis in malignant pleural mesothelioma.","description":"<h4>Background</h4>Malignant pleural mesothelioma (MPM) is an aggressive tumor but approximately 12% of patients survive more than 3 years. The biological differences underlying better outcomes are not known. Several targeted agents and immunotherapy have been ineffective. Hedgehog (Hh) is one emerging pathway. We compared the biological profiles of patients with different survival, investigating the most frequently altered genes, including the Hh pathway.<h4>Methods</h4>We analyzed 56 MPM. A 36-month overall survival (OS) cut-off divided patients into 32 normo (NS) and 24 long (LS) survivors. We used next generation sequencing to test 21 genes, immunohistochemistry to evaluate SMO expression. Mutation differences between NS and LS and their associations with clinical features were analyse","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2025-04-19T23:40:02.15Z","creation":"2025-04-19T23:40:02.15Z"},"accession":"S-EPMC7653142","cross_references":{"pubmed":["33209614"],"doi":["10.21037/tlcr-19-425"]}}